Hemostatic Profiles of Patients Who Underwent Transcatheter Versus Surgical Aortic Valve Replacement Versus

Jonathon Paul Fanning1, Shaun Roberts2, Chris Anstey3

  • 1Intensive Care Services, St. Andrew's War Memorial Hospital, Brisbane, Queensland, Australia; Faculty of Medicine, The University of Queensland, Queensland, Australia; Critical Care Research Group, The Prince Charles Hospital, Queensland, Australia.

PubMed

Insights

Transcatheter aortic valve replacement (TAVR) patients exhibit a more prothrombotic state compared to percutaneous coronary intervention (PCI) and surgical aortic valve replacement (SAVR) patients. This suggests current antithrombotic guidelines extrapolated from PCI may not be suitable for TAVR.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Interventional Cardiology

Background:

  • Current antithrombotic prophylaxis guidelines for transcatheter aortic valve replacement (TAVR) are largely derived from percutaneous coronary intervention (PCI) data.
  • The pathobiologic validity of extrapolating PCI antithrombotic strategies to TAVR remains uncertain.
  • Understanding early perioperative coagulation changes is crucial for optimizing TAVR antithrombotic management.

Purpose of the Study:

  • To investigate and compare temporal coagulation changes in the early perioperative period among patients undergoing TAVR, PCI, and surgical aortic valve replacement (SAVR).
  • To assess the hemostatic profiles of TAVR patients relative to PCI and SAVR cohorts.
  • To evaluate the clinical implications for current antithrombotic prophylaxis guidelines in TAVR.

Main Methods:

  • Prospective observational study involving 27 TAVR, 12 PCI, and 12 SAVR patients.
  • Blood samples collected at four time points: baseline, post-heparin, end-of-procedure, and 6 hours post-procedure.
  • Coagulation assessed using standard laboratory tests and advanced viscoelastic whole blood assays (ROTEM sigma, TEG 6s).

Main Results:

  • TAVR patients demonstrated a more prothrombotic hemostatic profile compared to PCI and SAVR patients.
  • Significant differences in prothrombotic state observed between TAVR and SAVR post-heparin, and between TAVR and PCI at 6 hours post-procedure.
  • ROTEM and TEG parameters showed good correlation but were not interchangeable.

Conclusions:

  • Patients undergoing TAVR exhibit a distinct, more prothrombotic hemostatic profile than those undergoing PCI or SAVR.
  • Findings challenge the current practice of extrapolating antithrombotic regimens from PCI to TAVR.
  • Further research is warranted to establish TAVR-specific antithrombotic strategies.